PM360 2019 Trailblazer Awards Respiratory Brand Champion Jenn Etheridge

Jenn Etheridge, Senior Marketing Manager, Genentech

Esbriet (pirfenidone) is one of two products on the market for idiopathic pulmonary fibrosis (IPF), a progressive, fatal lung disease where many patients remain untreated with a pharmacologic therapy. Jenn Etheridge decided the best way to raise awareness about IPF with patients was through local patient outreach programs (LPOPs) in targeted cities.

She worked with an external partner on patient educational programs with city selection based on where the largest educational need for patients is. Patient Ambassadors are present at every LPOP to infuse the authentic patient perspective into the conversation to encourage others to talk to their doctor about IPF and treatment options. In addition, the content and structure encourage partnership with one’s healthcare team by exploring questions for patients to ask so they can go to appointments prepared.

Jenn also elicited patient feedback in order to make changes to the LPOPs that would better suit patients’ needs. And now LPOPs will provide deeper education on specific topics—so patients interested in exploring supplemental oxygen, management of side effects, etc., can join a discussion on that specific topic.

Through this program, more than 1,000 patients and caregivers were educated about IPF, Esbriet, and the importance of building a strong relationship with their healthcare team, with overwhelmingly positive feedback on the programs.

Ads

You May Also Like

2018 Pharma Choice App Gold Winner Intouch Solutions and Regeneron

Intouch Solutions Regeneron Making Virtual a Reality A team of creatives, developers, and production ...

Get Wired for Sound

Prescriber insights are vital in guiding pharma brand marketing decisions and providing visibility into ...

PM360 2019 Innovative Product Healthy Conversations from Verywell

Healthy Conversations Verywell Rob Stephen, VP, Marketing rstephen@verywell.com Healthy Conversations is an interactive editorial ...